Study Name:
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer (CA209-77T)
Targeted Disease(s):
Lung Cancer
Purpose of Study:
The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.
Study Dates:
September 16, 2019 - September 30, 2024
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Bristol Myers Squibb
Sponsors:
Bristol Myers Squibb
Contact:
BMS Study Connect
855-907-3286
Clinical.Trials@bms.com
ClinicalTrails.gov Identifier:
NCT04025879